高昂费用及频发的不良反应：转移性肾细胞癌一线治疗用药卡博替尼的未来之路
杨晶莹, 谢英伟, 朱定军, 谢文练
High cost and frequent adverse events： the future of Cabozantinib for the first-line treatment of metastatic renal cell carcinoma
YANG Jing-ying, XIE Ying-wei, ZHU Ding-jun, XIE Wen-lian
岭南现代临床外科
.
2021, (04): 387
-391
.
DOI: 10.3969/j.issn.1009-976X.2021.04.003
